Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: First demonstration of N-channel function in humans
Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: First demonstration of N-channel function in humans
复制标题
DOI：
10.1097/00005344-199709000-00019
复制
发表时间：
1997-09-01
影响因子：
3
通讯作者：
Luther, RR
中科院分区：
文献类型：
--
作者：
McGuire, D;Bowersox, S;Luther, RR
SNX-111是第一个进入临床药物开发的神经元N型电压敏感性钙通道（VSCC）阻滞剂。潜在的治疗应用领域包括伤害性疼痛和神经性疼痛的治疗以及缺血性脑损伤后的神经保护。所提供的数据表明，SNX-111在人体中具有生物活性，并首次表明了人体N型VSCC的神经生理功能。
SNX-111 is the first neuronal N-type, voltage-sensitive calcium channel (VSCC) blocker to enter clinical drug development. Areas of potential therapeutic utility include treatment of nociceptive and neuropathic pain and neuroprotection after ischemic brain injury. The data presented demonstrate that SNX-111 is biologically active in humans and indicate for the first time a neurophysiologic function of N-type VSCCs in humans.